AU2023246216A1 - Pharmaceutical composition for treating tumors - Google Patents
Pharmaceutical composition for treating tumors Download PDFInfo
- Publication number
- AU2023246216A1 AU2023246216A1 AU2023246216A AU2023246216A AU2023246216A1 AU 2023246216 A1 AU2023246216 A1 AU 2023246216A1 AU 2023246216 A AU2023246216 A AU 2023246216A AU 2023246216 A AU2023246216 A AU 2023246216A AU 2023246216 A1 AU2023246216 A1 AU 2023246216A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- inhibitor
- pharmaceutical composition
- kras
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022060715 | 2022-03-31 | ||
| JP2022-060715 | 2022-03-31 | ||
| PCT/JP2023/012957 WO2023190748A1 (ja) | 2022-03-31 | 2023-03-29 | 腫瘍治療用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023246216A1 true AU2023246216A1 (en) | 2024-09-19 |
Family
ID=88202666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023246216A Pending AU2023246216A1 (en) | 2022-03-31 | 2023-03-29 | Pharmaceutical composition for treating tumors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250177406A1 (https=) |
| EP (1) | EP4473970A4 (https=) |
| JP (1) | JPWO2023190748A1 (https=) |
| KR (1) | KR20240167633A (https=) |
| CN (1) | CN118785911A (https=) |
| AU (1) | AU2023246216A1 (https=) |
| CA (1) | CA3244999A1 (https=) |
| MX (1) | MX2024010728A (https=) |
| WO (1) | WO2023190748A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4056580A4 (en) | 2019-11-07 | 2023-12-06 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING A PEPTIDE COMPOUND COMPRISING A STERICALLY HINDERED AMINO ACID |
| BR112022007535A2 (pt) | 2019-11-07 | 2022-07-12 | Chugai Pharmaceutical Co Ltd | Composto peptídico cíclico tendo ação inibitória de kras |
| US12312379B2 (en) | 2021-05-07 | 2025-05-27 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing cyclic compounds comprising N-substituted amino acid residues |
| KR20250085767A (ko) | 2022-09-29 | 2025-06-12 | 광조우 조요 파마테크 컴퍼니 리미티드 | 거대고리 유도체 및 이의 적용 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| TW202510852A (zh) * | 2023-07-20 | 2025-03-16 | 日商中外製藥股份有限公司 | 用於癌症之治療或預防的藥物 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107587A (en) | 1993-11-12 | 1998-08-16 | Univ Ramot | Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation |
| AU2004206046B2 (en) | 2003-01-21 | 2009-12-17 | Thallion Pharmaceuticals Inc. | Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| US9174998B2 (en) | 2013-12-25 | 2015-11-03 | Eisai R&D Management Co., Ltd. | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound |
| MX373231B (es) * | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2986999C (en) | 2015-06-23 | 2023-08-08 | Eisai R&D Management Co., Ltd. | Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide |
| US9861623B1 (en) | 2016-10-28 | 2018-01-09 | Macau University Of Science And Technology | Combination treatment of RAS-positive diseases with PDE-δ inhibitor and direct autophagy inhibitor |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| PE20260440A1 (es) | 2018-11-09 | 2026-02-19 | Hoffmann La Roche | Compuestos de anillo fusionado |
| WO2020173935A1 (en) | 2019-02-26 | 2020-09-03 | Boehringer Ingelheim International Gmbh | New isoindolinone substituted indoles and derivatives as ras inhibitors |
| CN114437065A (zh) | 2019-05-21 | 2022-05-06 | 益方生物科技(上海)股份有限公司 | 杂环化合物，其制备方法和用途 |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| WO2022031952A2 (en) * | 2020-08-07 | 2022-02-10 | City Of Hope | Treatments for cancers having kras mutations |
-
2023
- 2023-03-29 EP EP23780756.5A patent/EP4473970A4/en active Pending
- 2023-03-29 AU AU2023246216A patent/AU2023246216A1/en active Pending
- 2023-03-29 KR KR1020247029099A patent/KR20240167633A/ko active Pending
- 2023-03-29 WO PCT/JP2023/012957 patent/WO2023190748A1/ja not_active Ceased
- 2023-03-29 JP JP2024512718A patent/JPWO2023190748A1/ja active Pending
- 2023-03-29 CA CA3244999A patent/CA3244999A1/en active Pending
- 2023-03-29 MX MX2024010728A patent/MX2024010728A/es unknown
- 2023-03-29 CN CN202380024369.3A patent/CN118785911A/zh active Pending
- 2023-03-29 US US18/846,082 patent/US20250177406A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250177406A1 (en) | 2025-06-05 |
| JPWO2023190748A1 (https=) | 2023-10-05 |
| EP4473970A4 (en) | 2026-01-21 |
| KR20240167633A (ko) | 2024-11-27 |
| CA3244999A1 (en) | 2025-06-13 |
| CN118785911A (zh) | 2024-10-15 |
| MX2024010728A (es) | 2024-09-10 |
| EP4473970A1 (en) | 2024-12-11 |
| WO2023190748A1 (ja) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250177406A1 (en) | Pharmaceutical composition for treating tumors | |
| WO2022221227A9 (en) | Amino-substituted heterocycles for treating cancers with egfr mutations | |
| JP6855243B2 (ja) | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 | |
| AU2011273968B2 (en) | Pyrazolo-quinolines | |
| CN112472699A (zh) | 改善比生群及衍生物的治疗益处的组合方法 | |
| US20240293557A1 (en) | Proteolysis targeting chimeras and methods of use thereof | |
| US20230248740A1 (en) | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | |
| US20240343728A1 (en) | Compounds that inhibit pi3k isoform alpha and methods for treating cancer | |
| US20250235426A1 (en) | Pharmaceutical Combination and Use Thereof | |
| CA3213359A1 (en) | Alk-5 inhibitors and uses thereof | |
| US20230000876A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
| KR20140032586A (ko) | Ｐｔｅｎ 기능저하에 의한 ｅｇｆｒ-ｔｋｉ 저해제-내성 폐암의 방사선 치료용 약학 조성물 | |
| EP4656193A1 (en) | Pharmaceutical composition for treating tumors | |
| JP2024546846A (ja) | マントル細胞リンパ腫の治療のためのアベマシクリブ並びにＰＩ３Ｋ阻害剤及び／又はｍＴＯＲ阻害剤を含む薬剤の組み合わせ | |
| WO2014031856A1 (en) | Combination therapy using pi3 kinase and braf inhibitors | |
| US20230090742A1 (en) | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors | |
| EA049995B1 (ru) | Соединения, ингибирующие изоформу альфа pi3k, и способы лечения онкологического заболевания | |
| WO2024254266A1 (en) | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer | |
| EP4724151A1 (en) | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer | |
| WO2025157389A1 (en) | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors | |
| HK40107546A (zh) | 抑制PI3K同工型α的化合物和用於治疗癌症的方法 | |
| NZ617243A (en) | Combinations of akt and mek inhibitor compounds, and methods of use | |
| NZ617243B2 (en) | Combinations of akt and mek inhibitor compounds, and methods of use |